August 30, 2021 (FARGO, N.D.) – Agathos Biologics, a biotechnology company developing transformational science within a strong ethical and moral framework, today announced the company has been awarded $900,000 from the North Dakota Department of Agriculture Bioscience Innovation Grant (BIG) Program. Agriculture Commissioner Doug Goehring announced that nine grants have been awarded totaling $4.9 million to foster the growth of the bioscience industry in North Dakota. “Advances in bioscience have already transformed many sectors including agriculture and medicine,” Goehring said. “These grants will help North Dakota stay on the forefront of bioscience innovation.”
Agathos Biologics’ project funded by ND BIG will focus on challenges that limit patient access to advanced genetic medicines that can significantly impact quality of life—cost, availability, and ethical concerns. Company scientists will create new materials and methods for research and biomanufacturing and use them for drug development, which will address unmet medical needs and increase the availability of genetic medicines to more patients. The company will make these products and services available to the broader biotechnology industry through direct sales and licensing, partnerships, and collaborations.
“We are honored to receive this support from the State of North Dakota and thank the Commissioner and the Committee for their work on behalf of the citizens of the state,” said James Brown, Chief Executive Officer of Agathos Biologics. “We founded the company in North Dakota because its business-friendly environment, skilled workforce, and growing biotechnology ecosystem make it an ideal place to expand the company and achieve our goal to develop genetic medicine products and services that positively impact human health and are ethically acceptable to all.”
August 26, 2021 (FARGO, N.D.) – As we seek to build Agathos Biologics, it’s important to state our mission, values and strategy. We have taken the first step in this direction, describing our approach on our web site in the pages “Our Mission”, “Our Strategy” and “Good Science for a Better World” (collectively GSBW). We will look for opportunities to refine and further communicate in these areas, and one way to do this is to respond to relevant current events. Recently, Jason Fried, CEO of the software company Basecamp made a public statement about “Changes at Basecamp” and CTO David Hansson followed up with a post titled “new etiquette regarding societal politics at work”, which have garnered considerable news coverage and responses from many different perspectives. We believe Basecamp’s statement raises some important issues that we would like to address in the context of the culture of Agathos Biologics. Read the white paper in full here.
May 26, 2021 (FARGO, N.D.) – Agathos Biologics, a biotechnology company developing transformational science in biomanufacturing, biologic payload delivery, and cell and gene therapy within a strong ethical and moral framework, today announced the appointment of Jagadish Loganathan, Ph.D. as Director, Research and Development. Loganathan’s responsibilities include establishing research and development operations at Agathos’ Fargo, North Dakota facilities, recruiting and managing scientific staff, and leading internal and external programs.
Prior to joining Agathos Loganathan was a Scientist at the Indiana University School of Medicine where he studied the importance of the correct compartmentalization of different molecular signals mediated by natural compounds targeting cancer genes. His scientific experience includes work as a research associate at North Dakota State University (NDSU) targeting cancer cells in a hypoxic environment using nanoparticles and the molecular mechanism and pathophysiology of bronchial asthma in the different sexes. Previously as a postdoctoral fellow at NDSU he studied the chemotherapeutic effects of plant-derived small molecules and lentiviral vectors on pancreatic and lung cancer cells. Loganathan received his Ph.D. in microbiology from the University of Madras in Chennai, India.
“We are pleased to have Jagadish join Agathos during this critical time as we build our research and development capabilities and team,” said James Brown, CEO. “His accomplishments and experience in molecular biology, cell culture, and microbiology will enable him to effectively lead our efforts to develop new materials and methods for biomanufacturing and use them in our therapeutic programs.”
“I am excited to bring my skills and expertise to Agathos Biologics and pursue our mission as the good science company,” said Loganathan. “Our novel biomanufacturing and therapeutic products will provide scientific and medical benefits without ethical concerns about the origin or source of materials used in their development. I look forward to using my experiences building laboratory operations and mentoring others to quickly establish Agathos as a leader in ethical biotechnology.”